Vimarsana
Biggest News Aggregation in the World

Page 18 - Top Class Actions News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Top Class Actions. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Top Class Actions Today - Breaking & Trending Today

California Franchise Tax Board (FTB) LLC Fees $22M Class Action Settlement - Vimarsana News

California Franchise Tax Board (FTB) LLC Fees $22M Class Action Settlement

The California Franchise Tax Board (FTB) has agreed to pay $22 million to resolve claims it charged LLCs unconstitutional tax fees.

Comcast Xfinity Cable TV Deceptive Fees Arbitration Investigation - Vimarsana News

Comcast Xfinity Cable TV Deceptive Fees Arbitration Investigation

If you are a current or former Comcast Xfinity television customer, then you may have a claim for monthly overcharges.

Biden Administration Encourages Private Sector To Partner With Government Against Cyber Attacks - Vimarsana News

Biden Administration Encourages Private Sector To Partner With Government Against Cyber Attacks

At the Global Privacy Summit in Washington, D.C., government officials urged private companies to view them as a partner against cyber attacks so as to better respond to and protect against hacking.

9/11 Victim's Family Seeks Equal Split Of Seized Afghan Funds - Vimarsana News

9/11 Victim's Family Seeks Equal Split Of Seized Afghan Funds

The estate of a man who was killed on 9/11 and his family members have filed a class action lawsuit in an effort to freeze $3.5 billion in Afghan assets and ensure that the money is distributed equitably among the family members of the nearly 3,000 people killed in the attacks.

Rodan + Fields to Pay Out $38 M in Lash Boost Settlement - Vimarsana News

Rodan + Fields to Pay Out $38 M in Lash Boost Settlement

Rodan + Fields will pay $38 million to settle several class action suits against its Lash Boost serum. The plaintiffs claim the product's labeling misleads consumers and its isopropyl cloprostenate content makes it subject to FDA oversight.